July 6, 2026: In response to a request for public comments, NCHR wrote to the FDA strongly supporting the continuation of the National Youth Tobacco Survey for 2027-2029. NCHR emphasized that NYTS is essential for tracking youth tobacco and nicotine use, including e-cigarettes, nicotine pouches, and other emerging products, and for understanding whether new products contribute to combustible cigarette use, dual use, or sustained nicotine addiction. The survey provides critical data to guide prevention, enforcement, education, and evidence-based tobacco control policies that can be used to reduce addiction and dangerous heath habits by children and adolescents.
Read More »Nicotine & Tobacco
Testimony of Dr. Akashleena Mallick at the FDA TPSAC Meeting on ZYN Nicotine Pouch Products Submitted by Swedish Match U.S.A, Inc.
January 22, 2026 NCHR Comment to FDA: Dr. Akashleena Mallek told FDA we disagree that ZYN nicotine pouches are less dangerous than smoking. ZYN has never been tested in long-term studies to determine its impact on cancer, heart disease, and other serious diseases. It is especially harmful because it is marketed to children and teen non-smokers, creating an epidemic of nicotine addiction similar to the vaping epidemic among children a few years ago.
Read More »NCHR Written Comment to FDA on Modified Risk Tobacco Product (MRTP) Applications for ZYN Nicotine Pouch Products
January 21, 2026 NCHR Written Comment to FDA: ZYN says it is good for public health because it is less harmful than smoking. We disagree. It has never been tested in long-term studies to determine its impact on cancer, heart disease, and other serious diseases. It is very harmful because it is marketed to children and teen non-smokers, creating an epidemic of nicotine addiction similar to the vaping epidemic among children a few years ago.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee Meeting on Risks of 3 Heat Sticks And Other IQOS Tobacco Products
Diana Zuckerman spoke on behalf of NCHR and CPTF at Oct 2025 FDA Tobacco Advisory Committee TPSAC meeting on whether Phillip Morris heat sticks and other IQOS products should continue to be marketed as low risk. We pointed out that these products have evidence of substantial risks in the short-term and long-term risks are likely to be greater.
Read More »NCHR Public Comment on the Continued Implementation of the National Youth Tobacco Survey
In our public comment to the CDC, we strongly supported the continued operation of the National Youth Tobacco Survey (NYTS) for the 2026-2028 cycle. NYTS is the cornerstone of public health surveillance in this field and we reminded CDC and FDA that evaluating the youth use of tobacco products is an essential tool of U.S. public health strategies to reduce cancer, heart disease, and chronic diseases that are key to the MAHA movement.
Read More »